Endo in a Bite

This episode reviews major updates in lipid management for ASCVD risk reduction. Topics include revised LDL-C estimation equations, expanded clinical application of apolipoprotein B for residual atherogenic risk assessment, universal lipoprotein(a) screening, and cardiovascular kidney metabolic syndrome as a risk enhancing condition. The episode also discusses triglyceride referral thresholds, reproductive and inflammatory ASCVD ri...

This episode applies risk based lipoprotein targets across specific clinical scenarios for atherosclerotic cardiovascular disease risk reduction. It highlights how severe hypercholesterolemia, diabetes, subclinical atherosclerosis, hypertriglyceridemia, and clinical ASCVD are stratified using the same three tier framework of 100/130/90, 70/100/70, and 55/85/55. It emphasizes the role of coronary artery calcium in refining risk, the...

This episode reviews risk based lipoprotein targets for atherosclerotic cardiovascular disease risk reduction. It highlights LDL-C, non-HDL-C, and apolipoprotein B as key parameters, with goals stratified by overall ASCVD risk category. It emphasizes the three tier framework of 100/130/90 for low risk, 70/100/70 for intermediate risk, and 55/85/55 for high or very high risk patients. It also covers primary versus secondary preventi...

This episode reviews the clinical application of lipoprotein(a) and apolipoprotein B in cardiovascular risk assessment based on AHA ACC guidance. It emphasizes the genetic determination and stability of lipoprotein(a), supporting its role as a one time measurement for risk stratification, along with the importance of cascade screening in identifying inherited risk. The discussion outlines how lipoprotein(a) levels correlate with gr...

This episode reviews the importance of dyslipidemia screening across both pediatric and adult populations based on AHA ACC guidelines. It highlights the epidemiology and clinical impact of dyslipidemia, emphasizing the role of cumulative low density lipoprotein cholesterol exposure in determining lifetime cardiovascular risk. The discussion covers universal screening strategies, limitations of family history based screening, and pr...

This episode reviews the clinical significance of hypoglycemia in diabetes care, including its classification into Level 1, Level 2, and Level 3 events. The discussion highlights early recognition, variability in symptom thresholds, and the importance of prompt treatment to prevent severe outcomes. Key takeaways include the use of 15 to 20 grams of fast acting carbohydrates for conscious patients, appropriate use of glucagon in sev...

This episode reviews the evolution of vitamin D management frameworks, highlighting the shift from intake based recommendations by the National Academy of Medicine to the 2011 Endocrine Society’s laboratory driven approach, and back to a modern intake focused strategy in the 2024 guideline. The discussion emphasizes when vitamin D testing is appropriate, the role of 25 hydroxyvitamin D in assessing stores, and why routine screening...

This episode reviews clinical management of gastrointestinal symptoms associated with semaglutide therapy and strategies to maintain treatment when intolerance occurs. The discussion explains the role of delayed gastric emptying in nausea and highlights practical approaches including dietary modification, slower dose titration, and symptom directed therapy.
Additional topics include pregnancy planning with the recommended 8 week...

This episode reviews the cardiovascular kidney metabolic (CKM) syndrome framework introduced by the American Heart Association, which describes the interconnected progression of obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. The discussion highlights CKM staging and emphasizes early cardiometabolic risk recognition and preventive therapy including statins, blood pressure control, glucagon like peptide...

This episode reviews the American Heart Association PREVENT™ cardiovascular risk calculator and its role in modern primary prevention. The discussion highlights the shift from the pooled cohorts equation to contemporary risk prediction models that incorporate kidney function, cardiometabolic risk staging, and updated population data. Emphasis is placed on risk refinement strategies including coronary artery calcium scoring and lipi...

This episode reviews the 2025 ACE consensus approach to cost conscious obesity pharmacotherapy, emphasizing access driven treatment sequencing, payer mandated step therapy, and stage based medication selection for adiposity based chronic disease. Focus is placed on balancing clinical efficacy, affordability, and long term sustainability, with escalation and override strategies guided by therapeutic response and the presence of obes...

This episode reviews the 2025 ACE consensus on biologically informed lifestyle therapy for obesity and adiposity based chronic disease (ABCD), including personalized nutrition strategies to achieve and sustain an energy deficit, protein and micronutrient requirements to preserve lean mass and metabolic health, physical activity and resistance training targets for weight maintenance, the role of sleep and circadian regulation in ene...

This episode reviews the clinical component of the 2025 ACE consensus, shifting from identifying excess adiposity to staging adiposity based chronic disease (ABCD). It explains how clinicians assess obesity related complications, apply disease staging independent of BMI, and account for contributing factors such as medications, endocrine causes, genetics, psychological influences, and social determinants. The episode then connects ...

This episode examines the anthropometric component of the 2025 ACE consensus on obesity, emphasizing the role of BMI as a screening tool rather than a diagnostic endpoint. It outlines population specific BMI thresholds, the clinical need for assessing abdominal adiposity, and the importance of standardized waist circumference and waist to height ratio measurements in evaluating cardiometabolic risk. The discussion reinforces why bo...

This episode introduces the 2025 ACE consensus framework for obesity, reframing the condition as adiposity based chronic disease (ABCD) rather than a numeric weight diagnosis. It reviews the shift toward person centered, complication centric care, emphasizing the role of both anthropometric and clinical assessment in diagnosis and staging. The discussion highlights obesity related complications as the primary driver of disease seve...